Zenotech Laboratories Ltd.

BSE: 532039 SECTOR: Pharmaceuticals & Drugs  9208   43   2

56.30
-2.60 (-4.41%)
BSE: Today, 05:10 PM

Price Summary

Today's High

₹ 58.1

Today's Low

₹ 55.5

52 Week High

₹ 77.8

52 Week Low

₹ 0

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

343.6 Cr.

Enterprise Value

347.19 Cr.

No. of Shares

6.1 Cr.

P/E

15.59

P/B

4.37

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  12.88

CASH

2.41 Cr.

DEBT

6 Cr.

Promoter Holding

68.84 %

EPS (TTM)

₹  3.61

Sales Growth

62.91%

ROE

37.26 %

ROCE

15.26%

Profit Growth

1925.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year62.91%
3 Year41.05%
5 Year74.59%

Profit Growth

1 Year1925.03%
3 Year108.71%
5 Year25.52%

ROE%

1 Year37.26%
3 Year19.71%
5 Year10.28%

ROCE %

1 Year15.26%
3 Year11.35%
5 Year-6.75%

Debt/Equity

0.0849

Price to Cash Flow

19.45

Interest Cover Ratio

9.14787689269256

CFO/PAT (5 Yr. Avg.)

0.268085893450595

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 68.84 0
Sep 2022 68.84 0
Jun 2022 68.84 0
Mar 2022 68.84 0
Dec 2021 68.84 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 108.712831652001% for the Past 3 years.
  • The company has shown a good revenue growth of 41.0530957395922% for the Past 3 years.
  • The company has significantly decreased its debt by 14.6562 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 9.14787689269256.
  • Company’s PEG ratio is 0.00809907299037397.
  • The company has an efficient Cash Conversion Cycle of 39.2005833431332 days.
  • The company has a high promoter holding of 68.84%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 21.1781904454026.

 Limitations

  • Tax rate is low at -123.969579752154.
  • The company has a low EBITDA margin of 2.61910694846592% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 10.28 8.42 12.37 10.29 8.8
Total Expenditure 4.71 5.19 5.28 5.28 5.22
Operating Profit 5.56 3.23 7.09 5.01 3.57
Other Income 0.04 0.49 0.05 0.65 0.16
Interest 0.27 0.15 0.11 0 0
Depreciation 1.72 1.73 1.79 1.81 1.81
Exceptional Items 0 0 0 0 0
Profit Before Tax 3.61 1.85 5.24 3.85 1.93
Tax 0 -12.28 1.47 1.08 0.55
Profit After Tax 3.61 14.12 3.77 2.77 1.38
Adjusted EPS (Rs) 0.59 2.31 0.62 0.45 0.23

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 11.14 13.03 26.02 22.45 36.57
Total Expenditure 19.01 16.55 17.04 16.07 19.1
Operating Profit -7.87 -3.52 8.98 6.38 17.46
Other Income 2.37 4.71 1.17 0.41 0.63
Interest 2.45 0.12 0.89 1.55 1.22
Depreciation 3.9 4.2 4.85 6.46 6.97
Exceptional Items 0 0 6.37 0 0
Profit Before Tax -11.85 -3.13 10.78 -1.22 9.9
Tax 0 0 0 0 -12.27
Net Profit -11.85 -3.13 10.78 -1.22 22.18
Adjusted EPS (Rs.) -1.94 -0.51 1.77 -0.2 3.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 61.03 61.03 61.03 61.03 61.03
Total Reserves -19.01 -22.13 -11.4 -12.62 9.61
Borrowings 0 0 0 20.66 6
Other N/C liabilities 0.28 0.34 0.49 1.83 -10.41
Current liabilities 39.45 45.35 35.44 14.95 15.58
Total Liabilities 81.74 84.58 85.55 85.84 81.81
Assets
Net Block 44.43 43.11 48.73 74.23 70.91
Capital WIP 2.32 16.95 29.08 2.18 0.28
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 3.56 5.33 1.94 1.98 3.15
Other N/C Assets 0 0 0.1 0.1 0.1
Current Assets 31.42 19.19 5.71 7.35 7.37
Total Assets 81.74 84.58 85.55 85.84 81.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations -11.85 -3.13 10.78 -1.22 9.9
Adjustment 4.63 -0.07 -1.68 7.66 8.01
Changes in Assets & Liabilities -8.75 -10.38 2.56 -0.59 0.76
Tax Paid -0.28 -0.46 -0.28 -0.12 -1
Operating Cash Flow -16.25 -14.04 11.38 5.74 17.67
Investing Cash Flow -2.65 -16.19 -20.79 -4.82 -1.84
Financing Cash Flow 46.83 15.02 -2.7 0.45 -15.87
Net Cash Flow 27.92 -15.21 -12.11 1.38 -0.04

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 68.84 68.84 68.84 68.84 68.84
sun pharmaceutical... 57.56 57.56 57.56 57.56 57.56
daiichi sankyo com... 11.28 11.28 11.28 11.28 11.28
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 31.16 31.16 31.16 31.16 31.16
padmasree chigurup... 5.26 5.26 5.26 5.26 5.26
dr. jayaram chigur... 3.59 3.59 3.59 3.59 3.59
hardik bharat patel - - - - -
hardik b. patel - - 3.98 3.98 3.98
hardik b patel 3.98 3.98 - - -
ruchit bharat patel 1.99 1.99 1.99 1.99 1.99
zenotech llc 1.14 1.14 1.14 1.14 1.14

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Zenotech Laboratorie - Quaterly Results27 Jan 2023, 7:28PM Zenotech Laboratorie - Quaterly Results27 Jan 2023, 7:28PM Zenotech Laboratories informs about compliances-certificate10 Jan 2023, 5:42PM Zenotech Laboratorie - Quaterly Results28 Oct 2022, 7:16PM Zenotech Laboratorie - Quaterly Results28 Oct 2022, 7:16PM Zenotech Laboratories informs about board meeting 20 Oct 2022, 10:19AM Zenotech Laboratories informs about closure of trading window 26 Sep 2022, 1:01PM Zenotech Laboratories informs about newspaper advertisements29 Aug 2022, 12:34PM Zenotech Laboratories informs about 33rd AGM 27 Aug 2022, 4:35PM Zenotech Laboratorie - Quaterly Results22 Jul 2022, 6:50PM Zenotech Laboratorie - Quaterly Results22 Jul 2022, 6:50PM Zenotech Laboratories informs about board meeting14 Jul 2022, 10:53AM Zenotech Laboratories informs about certificate11 Jul 2022, 9:39AM Zenotech Laboratories informs about closure of trading window28 Jun 2022, 9:50AM Zenotech Laboratorie - Quaterly Results29 Apr 2022, 8:40PM Zenotech Laboratorie - Quaterly Results29 Apr 2022, 8:40PM Zenotech Laboratories informs about disclosure30 Mar 2022, 12:19PM Zenotech Laboratories informs about disclosure30 Mar 2022, 9:54AM Zenotech Laboratories informs about closure of trading window24 Mar 2022, 11:34AM Zenotech Laboratories informs about disclosure22 Mar 2022, 10:03AM Zenotech Laboratories informs about trading window closure28 Dec 2021, 11:01AM Zenotech Laboratories informs about trading window closure28 Dec 2021, 10:51AM Zenotech Laboratorie - Quaterly Results22 Oct 2021, 6:43PM Zenotech Laboratories informs about board meeting14 Oct 2021, 3:42PM Zenotech Laboratories informs about trading window closure27 Sep 2021, 10:30AM Zenotech Laboratories submits annual report2 Sep 2021, 3:40PM Zenotech Laboratories informs about board meeting17 Jul 2021, 2:15PM Zenotech Laboratories informs about outcome of board meeting23 Jan 2021, 3:35PM Zenotech Laboratories informs about clarification on price movements 4 Jan 2021, 10:28AM

Zenotech Laboratorie Stock Price Analysis and Quick Research Report. Is Zenotech Laboratorie an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Zenotech Laboratorie and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 17.6674 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Zenotech Laboratorie has a Debt to Equity ratio of 0.0849 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Zenotech Laboratorie , the EPS growth was 1925.01255650427 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Zenotech Laboratorie has OPM of 47.7523649600302 % which is a good sign for profitability.
     
  • ROE: Zenotech Laboratorie have a healthy ROE of 37.2552988996903 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Zenotech Laboratorie

X